Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression thumbnail image

 

Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms within days

Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually …

By Megan Neely
Megan Neely Profile Picture
Read more »

Amazon, Berkshire Hathaway, JPMorgan Chase health care venture launches website and announces its name: Haven

Amazon, Berkshire Hathaway, JPMorgan Chase health care venture launches website and announces its name: Haven thumbnail image

 

BOSTON – (BUSINESS WIRE) – March 6, 2019 – Today, the health care organization founded by Amazon (NASDAQ: AMZN), Berkshire Hathaway (NYSE: BRK.A, BRK.B), and JPMorgan Chase (NYSE: JPM), announced its name – Haven – and launched a new …

By Megan Neely
Megan Neely Profile Picture
Read more »

Charles Schwab CEO reveals how he tests job candidates by taking them to breakfast, having restaurant mess up their order by the Blaze

Charles Schwab CEO reveals how he tests job candidates by taking them to breakfast, having restaurant mess up their order by the Blaze thumbnail image

A person’s character is revealed during times of great pressure and distress. A great way to test out someone’s character is to observe how they react when things don’t go according to plan.

What if there were a way for …

By Megan Neely
Megan Neely Profile Picture
Read more »

Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia

Vor_logo_H

Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 million Series A financing round led by 5AM Ventures and RA Capital Management. Johnson & Johnson Innovation – …

By Molly Raddant
Molly Raddant Profile Picture
Read more »

Waltham biotech Morphic and Janssen to Collaborate in Deal Worth up to $750 Million

janssen

Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.

The collaboration between the companies focuses on …

By Molly Raddant
Molly Raddant Profile Picture
Read more »